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Background: We have witnessed significant progress in gene-based approaches to cancer prognostication, promising
early intervention for high-risk patients and avoidance of overtreatment for low-risk patients. However, there has
been less advancement in protein-based approaches, even though perturbed protein levels and post-translational
modifications are more directly linked with phenotype. Most current, gene expression-based platforms require
tissue lysis resulting in loss of structural and molecular information, and hence are blind to tumor heterogeneity
and morphological features.
Results: Here we report an automated, integrated multiplex immunofluorescence in situ imaging approach that
quantitatively measures protein biomarker levels and activity states in defined intact tissue regions where the
biomarkers of interest exert their phenotype. Using this approach, we confirm that four previously reported
prognostic markers, PTEN, SMAD4, CCND1 and SPP1, can predict lethal outcome of human prostate cancer.
Furthermore, we show that two PI3K pathway-regulated protein activities, pS6 (RPS6-phosphoserines 235/236) and
pPRAS40 (AKT1S1-phosphothreonine 246), correlate with prostate cancer lethal outcome as well (individual marker
hazard ratios of 2.04 and 2.03, respectively). Finally, we incorporate these 2 markers into a novel 5-marker protein
signature, SMAD4, CCND1, SPP1, pS6, and pPRAS40, which is highly predictive for prostate cancer-specific death.
The ability to substitute PTEN with phospho-markers demonstrates the potential of quantitative protein activity
state measurements on intact tissue.
Conclusions: In summary, our approach can reproducibly and simultaneously quantify and assess multiple protein
levels and functional activities on intact tissue specimens. We believe it is broadly applicable to not only cancer
but other diseases, and propose that it should be well suited for prognostication at early stages of pathogenesis
where key signaling protein levels and activities are perturbed.
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While tests for recurrent, validated gene mutations have
great prognostic and predictive value [1-5], these muta-
tions are relatively rare in early stage cancers. Multivariate
gene-based tests require homogenized tissue with variable
ratios of tumor and benign tissue resulting in less accurate
biomarker measurements [6,7]. In these types of tests,
phenotype must be inferred from genetic and mutational
patterns. In contrast, direct in situ measurement of protein
levels and post-translational modifications should more
directly reflect the status of oncogenic signaling pathways.
Thus, it is reasonable to expect a protein-based approach
to be highly valuable for prognostication.
A number of other issues complicate prognostic testing.
In prostate cancer, tumor heterogeneity is pronounced,
and sampling error can contribute to incorrect predictions.
Pathologist discordance in Gleason grading and tumor sta-
ging also renders prognostication in this multifocal disease
difficult. In an attempt to address these shortcomings, we
set out to develop an automated quantitative multiplex im-
munofluorescence imaging approach for intact tissue that
integrates morphological object recognition and molecular
biomarker measurements from defined, relevant tissue re-
gions at the individual slide level where the quantitative na-
ture of the signal intensity is positively correlated with the
amount of protein accessible on the tissue. We used this
system to predict lethal outcome from radical prostatec-
tomy tissue using four previously reported markers, PTEN,
SMAD4, CCND1 and SPP1 [8]. Importantly, we also dem-
onstrate that quantitative measurements of protein activity
states reflective of PI3K/AKT and mitogen-activated pro-
tein kinase (MAPK) signaling status, specifically pPRAS40
and pS6, are predictive of prostate cancer lethal outcome
based on univariate and multivariate analyses. As such,
they can substitute for PTEN, a highly validated prognostic
marker which itself regulates PI3K/AKT pathway signaling
[9-13]. Together these data identify a 5 marker novel le-
thal outcome predictive signature consisting of SMAD4,
CCND1, SPP1, pPRAS40 and pS6.
Results
Platform development
In order to develop an automated multiplex immunofluor-
escence imaging platform several technical requirements
had to be met: 1) ability to quantitate multiple markers
in a defined region of interest (i.e. in tumor versus sur-
rounding benign tissue), 2) rigorous tissue quality con-
trols, 3) balanced multiplex assay staining format, and
4) experimental reproducibility.
To address the first, we optimized long-pass diamidino-
2-phenylindole (DAPI), fluorescein isothiocyanate (FITC),
tetramethylrhodamine isothiocyanate (TRITC) and indodi-
carbocyanine (Cy5) filter sets to have sufficient excitation
energy and emission bandpass with minimal interferencebetween channels. We further separated biomarker sig-
nals from endogenous autofluorescence through spec-
tral unmixing of images (Figure 1A [14]). In order to
measure biomarkers in tumor epithelium only, we needed
to achieve “tissue segmentation”, distinguishing tumor from
benign areas. Segmentation was achieved using a com-
bination of feature extraction and protein co-localization
algorithms. Total epithelium was stained using Alexa488
conjugated anti-KRT8 and KRT18 antibodies, while
Alexa555 conjugated anti-KRT5 and TRIM29 antibodies
stained basal epithelium (Figure 1B) [15,16]. Using auto-
mated Definiens (Munich, Germany) image analysis, epi-
thelial structures with an outer layer of basal cells were
considered benign, while those lacking basal cells were
considered cancer [16]. Non-epithelial areas were consid-
ered stroma. Ultimately, quantitative biomarker values that
correlated with accessible protein were extracted only from
cancer epithelium (the ‘region of interest’; Figure 1B-D).
To evaluate tissue sample quality for study inclusion, we
assessed staining intensities of several protein markers in
benign tissue. Examination of a large number of prostate
tissue blocks of variable quality revealed that KRT8,
KRT18 and pSTAT3 (STAT3-phosphothreonine 705) in-
tensities in benign epithelial regions and capillary endothe-
lium, respectively, varied from ‘high’ to ‘low’ or ‘absent’,
according to tissue quality. On this basis, we categorized
formalin-fixed, paraffin-embedded (FFPE) prostate cancer
tissue blocks into four quality groups (Figure 2A and
Additional file 1: Table S1). Only blocks from the best two
groups were used to generate tumor microarray blocks
(TMA), thereby controlling for specimen degradation and
variability due to pre-analytic variation [17-19]. In total,
we procured and tested 508 unique prostatectomy sam-
ples with lethal outcome annotation available (Folio Bio-
sciences, Powell, OH). Of these, 418 passed quality testing
and were used for our TMA (Additional file 1: Table S2).
To balance biomarker signal levels in our multiplex assay
format, proteins with high expression levels, like cytokera-
tins and TRIM29 were visualized with directly conjugated
antibodies, while biomarkers with lower expression levels
required signal amplification through use of secondary and
tertiary antibodies. Using a test prostate TMA containing
low- and high-grade tumor material, dilutions of each
antibody were optimized to minimize background and
maximize specificity, and to ensure a dynamic range of
at least 3-fold difference between low and high signal
values (Figure 2B). Signals from consecutive TMA sec-
tions showed high reproducibility with typical R2 correl-
ation values above 0.9 and differences in absolute values
typically less than 10% (Figure 2B and data not shown).
Ability to predict lethal outcome
We first tested the platform using a four-protein signa-






Figure 1 Outline of experimental approach for automated, quantitative multiplex immunofluorescence and biomarker measurements
in defined regions of interest of prostatectomy tissue. A) Spectral profiles of each fluorophore in the spectral library used in the assay and
profiles for tissue autofluorescence signals (AFL) and bright autofluorescence (BAFL) signals, respectively. B) A general outline of staining
procedure for quantitative multiplex immunofluorescent biomarker measurements in tissue region of interest. SPP1 and SMAD4 were used as an
example. Region of interest marker antibodies (KRT8 (CK8) and KRT18 (CK18) for total epithelium and KRT5 (CK5) and TRIM29 for basal epithelium)
were directly conjugated to Alexa488 and Alexa 555, respectively. Biomarker antibodies were detected with a sequence of secondary and tertiary
antibodies, as described. Colors in the table illustrate unique spectral positions of emission peaks for the indicated Alexa fluorophore dyes.
C) A composite multispectral image (i) is unmixed into separate channels corresponding to AFL and BAFL, region of interest markers, and
biomarkers, as indicated (ii). D) Definiens script-based tissue segmentation and biomarker quantitation. Moving through panels 1-6, from the
composite image (1), first total epithelial regions are identified (2), followed by nuclear areas (3). The epithelial regions are further segmented
into tumor shown in red, benign in green, and undetermined in yellow (4). Gray color denotes non-epithelial regions, e.g. stroma and vessels (4).
Finally, biomarkers are quantified from tumor epithelium areas only, outlined in red (5 and 6).
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the Physician’s Health Study (PHS), the authors had
demonstrated that a multivariate model based on semi-
quantitative, pathologist-evaluated protein levels of PTEN,
SMAD4, CCND1 and SPP1 could predict lethal outcome.
We asked whether we could predict lethal outcome by
evaluating protein levels in an independent prostatectomy
cohort using our automated system instead. We acquired
monoclonal antibodies against all 4 markers and validated
them by specificity analyses as described (see Figure 3 and
Methods). Out of the 418 qualified cases in our TMA, 340
were found useful for analysis, attrition primarily being
due to cores displaced during sectioning (see Table 1 for
cohort description). Quantitative tumor epithelium bio-
marker levels were extracted from each sample and valueswere subjected to univariate analyses. PTEN, SMAD4 and
CCND1 were all found to be individually lethal outcome-
predictive with hazard ratios (HRs) of 2.74, 2.48 and 1.99,
respectively, while SPP1 did not have significant predictive
performance (Figure 4A).
Next, multivariate Cox and logistic regression ana-
lyses were conducted. The performance of the four-
marker model was determined as an area under the
curve (AUC) and a concordance index (CI) (Figure 4B
and Additional file 1: Table S3, respectively). For logistic
regression analyses, cases were defined as patients that
died from prostate cancer. The AUC was approximately
0.75 for the four markers in training mode, and 0.69 to
0.70 in test mode by logistic regression and Cox ana-
lyses, respectively (Figure 4B). A Kaplan-Meier curve
Intra-experimental reproducibility
Annotation and Quality control
B
A
Figure 2 Tissue annotation, quality control procedures and assay reproducibility. A) Tissue annotation and quality control procedures. Left:
A representative H&E-stained section of a human prostatectomy sample showing four (blue) and two (green) 1 mm diameter circles placed over
the regions with the highest and lowest Gleason pattern, respectively, as annotated by an expert pathologist. Two cores (1 mm diameter each)
were taken from two of the four blue regions to generate TMA blocks. Right: A consecutive section of the same prostatectomy sample was
stained with DAPI and KRT8/KRT18-Alexa488. Areas with bright staining of prostate epithelium by KRT8/18 cytokeratin antibodies were considered
good quality regions, while areas with little or no staining (as indicated within the yellow punctate area) were considered of low quality and not
deemed suitable for TMA construction. B) Intra-experimental reproducibility. Two consecutive sections from a prostate tumor test TMA were
stained in the same experiment. Images were acquired using the Vectra system and processed with a Definiens script. Scatter plots compare
mean values of KRT8/18, PTEN, and SMAD4 staining intensities from the same cores of the consecutive TMA sections. Linear regression curves,
equations, and R2 values were generated using Excel software.
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risk scores based on the four markers was generated by
a Cox model trained on the whole cohort. This curve
shows a clear survival difference between risk groups
(p < 10-5, see Figure 4C). Our mean AUC of 0.75 [95%
confidence interval (0.67, 0.83)] is comparable with per-
formance as described by Ding et al., with an AUC of
0.83 [95% confidence interval (0.76, 0.91)] [8], as indi-
cated by the large overlap in confidence intervals.
Incorporation of protein activity states as part of a novel
multivariate signature
Since protein activity states reflect functional events in the
tumors that are associated with aggressive behavior, we
tested whether our approach could quantitatively measure
not just protein levels but protein activity states as reflected
by post-translational modifications or altered sub-cellular
localization. Phosphorylation is a particularly well-studiedexample of post-translational modification; the stoichi-
ometry of protein phosphorylation at a particular site is an
indirect measure of the activity state of the parent signal-
ing pathway [20,21]. Specifically, we examined whether
the activity state of one or more signaling molecules in the
core PTEN-regulated signaling pathways PI3K/AKT and
MAPK could substitute for PTEN in the four-marker
model. PTEN protein, in contrast to the PI3K/AKT path-
way, is only altered in a subset of prostate cancers [11,22],
so our goal was to identify replacement phosphomarkers
that could be more broadly informative about PI3K/AKT
pathway activity states [22,23]. To this end, we obtained a
number of phospho-specific monoclonal antibodies (mAbs)
directed against key phosphoproteins and tested them for
technical suitability (Additional file 1: Table S4). Testing
included specificity analysis through western blot (WB)
and immunohistochemistry (IHC) before and after treat-
ment with the PI3K inhibitor LY294002, signal intensity in
PTEN CCND1 SMAD4

















































































































Figure 3 Validation of PTEN, CCND1, SMAD4, SPP1, pS6 and pPRAS40 antibody specificity. Doxycycline-inducible shRNA knockdown cell
lines were established for PTEN (A), CCND1 (B) and SMAD4 (C). Doxycycline treatment reduced the abundance of the target protein in all cases
as assessed by WB. Cell lines with high or low/negative levels of expression of PTEN (A), CCND1 (B) and SMAD4 (C) were also examined by WB
and IHC to further validate the specificity of the antibodies. SPP1 (D) antibody detected an SPP1-specific band and an additional band at a lower
molecular weight as assessed by WB in PC3 cells, while the SPP1-specific upper band was significantly decreased in low SPP1-expressing BxPC3
cells. The staining intensity of the SPP1 antibody in PC3 and BxPC3 cells by IHC correlated well with the relative intensity of the SPP1-specific
band detected by WB. The specificity of pS6 and pPRAS40 antibodies (E) was validated in DU145 cells. LY294002 treatment significantly reduced
phosphorylation of RPS6 and AKT1S1 (PRAS40), as shown by WB and IHC, respectively.
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stability [19,23] based on signal preservation across
prostate cancer FFPE samples (Figure 3). We included
phospho-markers because PI3K/AKT pathway activity is
often independent of PTEN protein status [12,13]. Based
on these criteria, the following phospho-specific antibodies
were selected and tested for univariate and multivariate le-
thal outcome predictive performance: p90RSK-T359/S363,
pPRAS40-T246, and pS6-S235/236 (Cell Signaling Tech-
nology, Danvers, MA [23];). We also selected an anti-






Age at diagnosis - mean (SD)
Median followup years
DOD: dead of disease. SD: standard deviation.nucleus when the PI3K pathway is activated [24]. When
subjected to univariate analysis, pPRAS40 and pS6 had
significant univariate performance with HRs of 2.03 and
2.04, respectively, comparing signal values of the top one-
third to bottom two-thirds in a Kaplan-Meier analysis
(Figure 5A). The other candidate markers did not reach
significance level for univariate performance (Figure 5A).
We next examined the performance of the four original
markers without PTEN. The AUC (train) dropped from
0.75 to 0.72-0.73, and addition of either pS6 (in essence
substituting pS6 for PTEN) or substitution with pPRAS40current study







Cox Model Logistic Regression
Mean Values Mean Values
Markers Mean AUC Low 95% High 95% Markers Mean AUC Low 95% High 95%
4 Markers Cox Test 0.701 0.575 0.817 4 Markers Logit Test 0.693 0.568 0.812
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Figure 4 QMIF assay performance with known 4-markers prognostic signature. A) Kaplan-Meier curves for survival as a function of single
biomarker protein expression in the study cohort. B) Univariate survival analysis. The population with the top 1/3 of risk score values was
separated from the population with the bottom 2/3 of risk scores. P values (P) and HR are annotated. C) Multivariate Cox regression and logistic
regression analyses of survival prediction for our study cohort. The marker combinations were used to develop models based on training and
testing on the whole cohort. 4 markers: PTEN, SMAD4, CCND1, SPP1. Logit: Logistic Regression. D) Kaplan-Meier curve for survival as a function of
time generated by a Cox model trained on the whole cohort using the 4 markers. The lowest 2/3 of risk scores was used as threshold for
population separation. P value (P) is annotated.
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despite their univariate performance (data not shown).
However, substitution of PTEN with both pS6 and
pPRAS40 increased AUC (train) values to between ~0.76
and ~0.77 (Figure 5B). The corresponding Kaplan-Meier
curve for the three markers together with pS6 + pPRAS40
showed significant separation of the top 1/3 from the bot-
tom 2/3 of the cohort (p = 1.3 × 10-5; Figure 5C). These re-
sults demonstrate that we can successfully replace PTEN,
a known lethal outcome-predictive tumor suppressor, with
two pathway activity markers, pS6 and pPRAS40, for the
development of a new lethal outcome-predictive signature.
Discussion
The goal of this work was to establish an automated im-
aging platform that accurately and reproducibly inte-
grates morphological and protein-level information. We
assessed platform performance through direct compari-
son with a previous study by using the same 4 markersreported to predict lethal outcome. While paired data
comparing the methods are not available, a simple meta-
analysis of the two studies estimates a non-significant dif-
ference in mean AUC of 0.08 [95% confidence interval
(-0.03, 0.19)]. Differences in performance may be due to
methodological differences between the two studies. First,
we only used monoclonal antibodies validated for specifi-
city through siRNA oligo-mediated knock down in West-
ern blotting and immunohistochemistry (Figure 3), while
two of the antibodies used in the PHS study were poly-
clonal and thus not ideal for continued prospective appli-
cation. Moreover, the quantitative measurements in this
study were fully automated, while theirs relied on patholo-
gist interpretation, and hence overall would be expected
to be slightly less reproducible. Finally, our cohort in-
cluded a higher proportion of Gleason ≤6 cases for which
lethal outcome would be more difficult to predict than for
higher grade cases and lethal outcome prediction was fur-
ther limited by a median follow-up of 11.92 years which is
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Figure 5 Phospho markers are predictive of prostate cancer outcome. A) Kaplan-Meier curves for survival as a function of single biomarker
protein expression in the study cohort (pS6, pPRAS40, FOXO3, p90RSK). B) Univariate survival analysis. The population with the top 1/3 of risk
score values was separated from the population with the bottom 2/3 of risk scores. P values (P) and HR are annotated. C) Multivariate Cox
regression and logistic regression analyses of survival prediction for our study cohort. The marker combination was used to develop models based
on training and testing on the whole cohort. 3 + pS6 + pPRAS40: SMAD4, CCND1, SPP1, pS6, pPRAS40. Logit: Logistic Regression. D) Kaplan-Meier
curve for survival as a function of risk scores generated by a Cox model trained on the whole cohort using the 3 + pS6 + pPRAS40 markers. The
lowest 2/3 of risk scores was used as threshold for population separation. P value (P) is annotated.
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odological distinctions and the assessment of difference in
AUCs, we conclude that our results are comparable, dem-
onstrating an important proof-of-concept for this fully au-
tomated platform and prognostication independent of
human interpretation.
An important application of this platform is the ability
to incorporate protein activation states as biomarkers.
The tumor suppressor PTEN, a highly outcome-predictive
marker, is altered in only 15-20% of early stage prostate
cancers, yet is often functionally inactivated through a var-
iety of other mechanisms that would be reflected in al-
tered PI3K/AKT pathway activity [12]. We here show that
phospho-specific mAbs measuring activity states of signal-
ing molecules in the core PI3K and MAPK pathways can
substitute for PTEN, and identify pPRAS40 and pS6 as
novel, lethal outcome-predictive markers for prostate can-
cer. The phosphorylation of these markers is directlycorrelated with the pathway activity state of the PI3K
pathway, and both of them are required for both PI3K and
MTOR complex 1 (mTORC 1) signaling [23,25]. AKT1S1
(PRAS40) contains a consensus phosphorylation motif
and is a direct substrate for AKT, a mediator of PI3K sig-
naling [26], while RPS6 is phosphorylated at Ser235/236
by p70S6 kinase. Interestingly, PRAS40 is required for
mTORC 1 signaling to p70S6 kinase, which, in turn, en-
ables p70S6 kinase to phosphorylate RPS6 at Ser235/236.
We incorporate these 2 markers into a novel lethal out-
come predictive five-marker signature for radical prosta-
tectomy: SMAD4, CCND1, SPP1, pPRAS40 and pS6 and
report its performance. To our knowledge, this is the first
study that identifies pPRAS40 and pS6 as prognostic
markers for prostate cancer.
Over the last few years various quantitative protein-
based in situ technologies have been developed with
varying degrees of success. The pioneering automated
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surements is one example [27]. While useful for tissues
where single markers can define region of interest, it does
not incorporate spectral unmixing and feature extraction
capabilities rendering it less suitable for multiplexing and
hence problematic for heterogeneous tumors like prostate
cancer. Another example is the Aureon platform, which
was specifically developed for prostate cancer prognosis
[28]. While in some ways similar to the platform we report
here, the Aureon platform was developed prior to recent
significant advances in automated imaging and biological
discoveries in prostate cancer [8]. In this platform, mor-
phological analyses were done on hematoxylin and eosin
(H&E)-stained slides, and biomarkers (AMACR and AR)
were measured from tissue regions defined by AMACR, a
heterogeneously expressed marker present in only ~70-
90% of prostate cancer patients, and hence not informative
in all cases [16]. Furthermore, full automation was not
possible with the first generation imaging software used at
the time of development (Definiens Enterprise Image
Intelligence Suite [28,29];). Robust tissue segmentation al-
gorithm and quantitative biomarker measurements can
now be achieved in tumor epithelium regions by combin-
ing Vectra multispectral image decomposition with the
programmable Definiens Tissue Developer, The resulting
automated approach is highly sensitive, operates without
subjective intervention, and can successfully evaluate very
small amounts of cancer tissue.
We propose that PI3K/AKT pathway activity state mea-
surements might be more informative in early prostate
cancer lesions than PTEN. In ongoing clinical studies on
early stage prostate cancer biopsy cohorts we are further
testing this notion.
Conclusions
In summary, we have developed a multiplex immunofluor-
escence in situ imaging platform with automated, objective
biomarker measurements able to predict lethal outcome
using prostatectomy tissue independent of pathologist in-
terpretation. Importantly, we demonstrate the ability to in-
corporate quantitative measurements of protein activity
states, as reflected by post-translational modifications, into
a multivariate protein predictor of lethal outcome, and
identify pPRAS40 and pS6 as novel predictive markers for
prostate cancer-specific death. We believe that this plat-
form is broadly applicable across disease states. We are
currently applying it to the development of a prognostic
prostate cancer biopsy test for early stage lesions where
tissue amounts are often limited.
Methods
Reagents and antibodies
All antibodies and reagents used in this study were pro-
cured from commercially available sources as describedin Additional file 1: Table S4. Anti-FITC mAb-Alexa568,
anti-KRT8-Alexa488, anti-KRT18-Alexa488, anti-KRT5-
Alexa555 and anti-TRIM29-Alexa555 were conjugated
with Alexa dyes, in-house using appropriate protein con-
jugation kits, according to manufacturer's instructions
(LifeTechnologies, Grand Island, NY).
Acquisition, processing and quality control of formalin-
fixed, paraffin-embedded (FFPE) prostate cancer tissue
blocks
We acquired a cohort of FFPE human prostate cancer tis-
sue blocks with clinical annotations and long-term patient
outcome information from Folio Biosciences (Powell, OH).
Samples had been collected with appropriate institutional
review board approval (Phylogeny protocol #001, Quorum
Review IRB, 1601 Fifth Avenue, Suite 1000, Seattle WA
98101, file #25552/1) and all patient records were de-
identified. We included a number of FFPE human prostate
cancer tissue blocks from other commercial sources
(BioOptions, Brea, CA; Cureline, So. San Francisco, CA;
ILSBio, Chestertown, MD; OriGene, Rockville, MD) to
validate individual antibody and combined multiplex
staining format staining intensities, to develop quality con-
trol procedures, to assess intra-experiment reproducibility
studies, and to confirm specificity of staining on prostate
tumor tissue.
Between 10 and 12 sections (5 μm cuts) were produced
from each FFPE block. The last section was stained with
H&E and scanned with an Aperio (Vista, CA) XT system.
H&E stained images were deposited into the Spectrum
database (Aperio, Vista, CA) for remote reviewing and cen-
tralized Gleason annotation in a blinded manner by expert
Board-Certified anatomical pathologists using ImageScope
software (Aperio, Vista, CA). Annotated circles correspond-
ing to 1 mm cores were placed over four areas of highest
and two areas of lowest Gleason patterns on each prosta-
tectomy sample using current criteria (Figure 2A) [30].
Tissue quality control procedure
A 5 μm section from each FFPE block was stained with
anti-pSTAT3 rabbit mAb, anti-STAT3 mouse mAb and re-
gion of interest markers, as described below. Slides were
examined under a fluorescence microscope. Based on stain-
ing intensities and autofluorescence, tissues were qualita-
tively graded into four categories as shown in Additional
file 1: Table S1 and Figure 2A. FFPE blocks belonging to
the top two quality categories were included for the study.
Cell line controls
Selected cell lines to be used as positive and negative
controls were grown under standard conditions and
treated with drugs and inhibitors before harvesting as in-
dicated (Additional file 1: Table S5). For further details,
see Additional file 2: Materials and methods.
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TMA blocks were prepared using a modified agarose block
procedure [31]. Three pairs of TMA blocks (MPTMAF1A
and 1B, 2A and 2B, 3A and 3B, respectively) with 91, 170,
and 157 annotated prostate tumor samples were con-
structed (see Additional file 1: Table S2 and Additional
file 2: Materials and methods).
A smaller test TMA was generated from commercially
available FFPE prostate tumor cases with only limited
(Gleason score) annotation. This TMA was used to com-
pare PTEN values with phosphomarkers prior to the
main cohort study and to confirm reproducibility. Re-
producibility was demonstrated by comparing individual
marker signals on consecutive sections of the test TMA
(Additional file 1: Table S2 and Figure 2B).
Slide processing and quantitative multiplex
immunofluorescence (QMIF) staining protocol
TMA sections were cut at 5 um thickness and placed on
Histogrip (LifeTechnologies, Grand Island, NY) coated
slides. Slides were baked at 65°C for 30 min, deparaffinized
through serial incubations in xylene, and rehydrated
through a series of graded alcohols. Antigen retrieval
was performed in 0.05% citraconic anhydride solution
for 45 min at 95°C using a PT module (Thermo Scientific,
Waltham, MA). Autostainers 360 and 720 (Thermo Scien-
tific, Waltham, MA) were used for staining.
The staining procedure involved two blocking steps
followed by four incubation steps with appropriate washes
in between. Blocking consisted of a biotin step followed by
Sniper reagent (Biocare Medical, Concord, CA). The first
incubation step included anti-biomarker 1 mouse mAb
and anti-biomarker 2 rabbit mAb. The second step in-
cluded anti-rabbit IgG Fab-FITC and anti-mouse IgG
Fab-biotin, followed by a third “visualization” step that in-
cluded anti-FITC mAb-Alexa568, streptavidin-Alexa633
and fluorophor-conjugated region of interest antibodies
(anti-KRT8-Alexa488, anti-KRT18-Alexa488, anti-KRT5-
Alexa555 and anti-TRIM29-Alexa555). Finally, sections
were incubated with DAPI for nuclear staining (for a stain-
ing format outline, see Figure 1B). Slides were mounted
with ProlongGold (LifeTechnologies, Grand Island, NY)
and coverslipped. Slides were kept at -20°C overnight be-
fore imaging and for long-term storage. A full set of 6
MPTMAF slides were stained in a single staining session
for the various antibody combinations encompassing all
biomarkers tested.
Antibody validation
mAb specificity was tested by WB before and after
knock down. To test the specificity of mAbs against
PTEN, SMAD4 and CCND1, we employed inducible
shRNA knockdown of the protein markers of interest.
Briefly, DU145 cells with inducible shRNA were generatedby transducing naïve DU145 cells with a virus carrying
pTRIPZ (Thermo Scientific, Waltham, MA). Cells were
stably selected using 2 μg/ml puromycin for a week. Sub-
sequently, cells were induced with either 0.1 μg/ml or
2 μg/ml of doxycycline for 72 hours. Cells were trypsinized
and processed either for RNA extraction or cell lysate gen-
eration. The best shRNA for each protein marker was
confirmed first by RT-PCR and then by western blot. Anti-
bodies were considered specific when the expected mo-
lecular band size decreased upon shRNA induction on
western blot.
To test mAb against SPP1, we used cell lines with high
or low SPP expression. Lysates from these cell lines (as
shown in Figure 3) were also used for Western blotting.
The antibody to SPP1 reveals a background band in the
BxPC3 cell line that is detectable by western blotting and
migrates with a lower apparent molecular weight than
SPP1. However, IHC with diamino benzidine (DAB)-based
permanent staining against SPP1 reveals almost no detect-
able background in the BxPC3 cells, confirming the speci-
ficity of antibody-based recognition of SPP1. This suggests
that the mAb against SPP1 might cross-react with a dena-
tured protein sequence detectable by Western blotting
that is not detectable in its native conformation by IHC.
The clean background shows that the antibody is highly
specific for SPP1 when used for IHC.
To test anti-phospho antibodies against members of the
AKT signaling pathway, DU145 cells were serum starved
overnight, treated with the PI3K inhibitor LY294002 at
10 μM for 2 hours, and lysed. Lysates from cells treated
with inhibitor were used as negative controls for Western
blots; lysates from cells grown in standard conditions were
used as positive controls.
20 μg of cell lysates were run on a 4-15% Criterion TGX
precast gel (Bio-Rad, Hercules, CA). Afterwards, the gel
was transferred onto nitrocellulose membrane using iBlot
(LifeTechnologies, Grand Island, NY). The primary anti-
body dilution was used according to product data sheet
recommendation. The membrane was developed using
SuperSignal West Femto Maximum Sensitivity Substrate
(Thermo Scientific, Waltham, MA). Images were captured
using the FluroChem Q system (Protein Simple, Santa
Clara, CA). Images were processed using AlphaView (Pro-
tein Simple, Santa Clara, CA) and ImageJ [32].
For testing by IHC before and after target knock down
FFPE cell pellets from cell lines treated as described above
were assembled together in a TMA block. 5 μm sections
were cut and dried at 60°C for an hour before deparaffini-
zation in three changes of xylene and rehydration in a
series of descending ethanol washes. The slides were
heated in 0.05% citraconic anhydride (Sigma, Saint Louis,
MO) at 95°C for 40 min for antigen retrieval. Slides were
stained using the Lab Vision™ UltraVision™ LP Detection
System: HRP Polymer/DAB Plus Chromogen Kit (Thermo
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tions. Slides were scanned with an Aperio Scanscope AT
Turbo system (Aperio, Vista, CA). Images were analyzed
with Aperio ImageScope software (Aperio, Vista, CA).Image acquisition
Two Vectra Intelligent Slide Analysis Systems (Perkin-
Elmer, Waltham, MA) were used for automated image
acquisition. DAPI, FITC, TRITC and Cy5 long pass filter
cubes were optimized to allow maximum spectral reso-
lution and minimize cross-interference between fluoro-
phores. Vectra 2.0 and Nuance 2.0 software packages
(Perkin Elmer, Waltham, MA) were used for automated
image acquisition and development of the spectral li-
brary, respectively.
TMA acquisition protocols were run in an automated
mode according to manufacturer instructions (Perkin-
Elmer, Waltham, MA). Two 20X fields per core were
imaged using a multispectral acquisition protocol that in-
cluded consecutive exposures with DAPI, FITC, TRITC
and Cy5 filters. To ensure reproducibility of biomarker
quantification, light source intensity was calibrated with
the X-Cite Optical Power Measurement System (Lumen
Dynamics, Mississauga, ON, Canada) prior to image ac-
quisition for each TMA slide. Identical exposure times
were used for all slides containing the same antibody com-
bination. To minimize intra-experiment variability, TMA
slides stained with the same antibody combinations were
imaged on the same Vectra microscope.
A spectral profile was generated for each fluorescent dye
as well as for FFPE prostate tissue autofluorescence. Inter-
estingly, two types of autofluorescence were observed in
FFPE prostate tissue. A typical autofluorescence signal was
common in both benign and tumor tissue, whereas atyp-
ical “bright” autofluorescence was specific for bright gran-
ules present mostly in epithelial cells of benign tissue. A
spectral library containing a combination of these two
spectral profiles was used to separate or “unmix” individual
dye signals from autofluorescent background (Figure 1A
and C).Image analysis
We developed an automated image analysis algorithm
using Definiens Developer XD (Definiens AG, Munich,
Germany) for tumor identification and biomarker quan-
tification. For each 1.0 mm TMA core, two 20X image
fields were acquired. Vectra multispectral image files
were first converted into multilayer TIFF format using
inForm (PerkinElmer, Waltham, MA) and a customized
spectral library, then converted to single layer TIFF files
using BioFormats (OME [33]). Single layer TIFF files
were imported into the Definiens workspace using a cus-
tomized import algorithm so that for each TMA core,both of the image field TIFF files were loaded and ana-
lyzed as “maps” within a single “scene”.
Autoadaptive thresholding was used to define fluores-
cent intensity cut-offs for tissue segmentation in each in-
dividual tissue sample. Tissue samples were segmented
using DAPI along with fluorescent epithelial and basal cell
markers to allow classification as epithelial cells, basal cells
and stroma, and were further compartmentalized into
cytoplasm and nuclei. Benign prostate glands contain basal
cells and luminal cells, whereas prostate cancer glands lack
basal cells and have smaller luminal profiles. Therefore, in-
dividual gland regions were classified as malignant or be-
nign based on the relational features between basal cells
and adjacent epithelial structures combined with object-
related features, such as gland size (see Figure 1D). Fields
with artifactual staining, insufficient epithelial tissue or
out-of-focus images were removed prior to quantification.
Epithelial marker and DAPI intensities were quantitated
in benign and malignant epithelial regions as quality con-
trol measurements. Biomarker intensity levels were mea-
sured in the cytoplasm, nucleus or whole cancer cell based
on predetermined subcellular localization criteria. Mean
biomarker pixel intensity in the cancer compartments was
averaged across maps with acceptable quality parameters
to yield a single value for each tissue sample and cell line
control core.
Patient cohort composition
Table 1 describes the composition of the prostatectomy
cohort used in the current study.
Marker value determination
As each sample was represented by two cores, we gener-
ated an aggregate score for each marker based on correl-
ation direction. For markers correlated positively with
lethality we used the core with the highest value; for
negatively-correlated markers we used the core with the
lowest value. For example, for the tumor suppressor
SMAD4, which was present on all stained sections, we
used the lowest core value for the two cores (Figure 6).
Univariate analyses
Univariate cox models were trained for each biomarker.
For each marker, the hazard ratio and log rank p-value
were calculated to compare the populations consisting
of the top one-third and bottom two-thirds of the risk
scores for positively correlated markers, and populations
consisting of the bottom one-third and top two-thirds of
risk scores for negatively correlated markers (Figures 4A
and 5A).
Multivariate analyses
We used multivariate analyses to determine the ability of
the marker set to predict lethal outcome. We leveraged two
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Figure 6 Outline of statistical analysis flow. For each patient, two tissue cores from the highest Gleason area were placed into TMA blocks.
Mean values of biomarker expression in the tumor epithelium region of each TMA core were used for analysis, resulting in two biomarker values
per patient. For PTEN, SMAD4, and pS6, the lowest value from the two cores was used for analysis. For CCND1, SPP1, p90RSK, pPRAS40, and
FOXO3, the highest value from the two cores was used. Using these values, 10,000 bootstrap training samples were generated and both
multivariate Cox and Logistic Regression models were trained on each training sample. Testing was performed on the complement set. Given the
cohort included censored data, we used both CI and AUC to estimate the model performance. The marker combinations that were tested in the
models were as follows: 4 markers (PTEN, CCND1, SMAD4, SPP1), 3 markers (CCND1, SMAD4, SPP1), and 3 markers with each of the following
combinations of phospho markers: pS6, pPRAS40, and [pS6 + pPRAS40].
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bootstrap training samples were generated, and both multi-
variate Cox models and logistic regression models were
trained on each training sample. Testing was performed on
the complement set. CI and AUC were used to estimate
model performance. Kaplan-Meyer curves were generated
to compare the population with the bottom two-thirds of
risk scores to the population with the top one-third of risk
scores. Receiver operating characteristic curves were gener-
ated for the whole cohort based on the risk scores from the
logistic regression model. Figure 6 presents an outline of
the multivariate analysis approaches.Additional files
Additional file 1: Table S1. Tissue grading. Table S2. TMA Maps.
Table S3. Concordance index. Table S4. Antibodies. Table S5. Cell line
controls.
Additional file 2: Materials and methods.
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